ATE531725T1 - Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen - Google Patents

Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen

Info

Publication number
ATE531725T1
ATE531725T1 AT08726179T AT08726179T ATE531725T1 AT E531725 T1 ATE531725 T1 AT E531725T1 AT 08726179 T AT08726179 T AT 08726179T AT 08726179 T AT08726179 T AT 08726179T AT E531725 T1 ATE531725 T1 AT E531725T1
Authority
AT
Austria
Prior art keywords
treatment
egfr
inhibitor
gene
respond
Prior art date
Application number
AT08726179T
Other languages
English (en)
Inventor
Patrick Muraca
Original Assignee
Nuclea Biomarkers Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuclea Biomarkers Llc filed Critical Nuclea Biomarkers Llc
Application granted granted Critical
Publication of ATE531725T1 publication Critical patent/ATE531725T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08726179T 2007-02-27 2008-02-27 Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen ATE531725T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90369407P 2007-02-27 2007-02-27
PCT/US2008/002602 WO2008106175A2 (en) 2007-02-27 2008-02-27 Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors

Publications (1)

Publication Number Publication Date
ATE531725T1 true ATE531725T1 (de) 2011-11-15

Family

ID=39716322

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08726179T ATE531725T1 (de) 2007-02-27 2008-02-27 Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen

Country Status (6)

Country Link
US (4) US20080206777A1 (de)
EP (2) EP2114990B9 (de)
AT (1) ATE531725T1 (de)
DK (2) DK2413142T3 (de)
ES (2) ES2412432T3 (de)
WO (1) WO2008106175A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313641A1 (en) * 1997-12-12 1999-06-24 Digene Corporation Universal collection medium
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
US7439016B1 (en) * 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
JP2011518333A (ja) * 2008-04-17 2011-06-23 キアジェン ゲイサーズバーグ インコーポレイテッド 標的核酸の存在を判別するための合成プローブを用いた組成物、方法、およびキット
TWI419974B (zh) 2008-10-27 2013-12-21 Qiagen Gaithersburg Inc 於自動平台上之快速結果雜交捕捉法
EP2419522A4 (de) * 2009-04-17 2012-10-31 Glen Weiss Verfahren und kits zur prognose des therapieergebnisses von tyrosinkinasehemmern
AU2010242867B2 (en) 2009-05-01 2016-05-12 Qiagen Gaithersburg, Inc. A non-target amplification method for detection of RNA splice-forms in a sample
EP2478087B1 (de) 2009-09-14 2017-01-18 QIAGEN Gaithersburg, Inc. Zusammensetzungen und verfahren zur rückgewinnung von nukleinsäuren oder proteinen aus in zytologischen medien fixierten gewebeproben
WO2011094514A1 (en) * 2010-01-29 2011-08-04 Qiagen Gaithersburg, Inc. Methods and compositions for sequence-specific purification and multiplex analysis of nucleic acids
JP2013517803A (ja) 2010-01-29 2013-05-20 キアジェン ゲイサーズバーグ インコーポレイテッド サンプル中のｈｐｖの存在を決定および確認する方法
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
EP2572001A2 (de) 2010-05-19 2013-03-27 QIAGEN Gaithersburg, Inc. Verfahren und zusammensetzungen für sequenzspezifische reinigung und multiplex-analyse von nukleinsäuren
WO2012094059A2 (en) * 2010-11-10 2012-07-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing early stage non-small cell lung cancer
EP2678442B1 (de) 2011-02-24 2019-01-16 QIAGEN Gaithersburg, Inc. Materialien und verfahren für den nachweis von hpv-nukleinsäuren
CN103926408A (zh) * 2014-04-30 2014-07-16 天津医科大学肿瘤医院 一种用于预测nsclc病人预后的试剂盒及骨桥蛋白作为特异标记物的应用
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CN116098856B (zh) * 2023-01-16 2024-06-21 四川大学华西医院 光固化水凝胶复合核酸传递系统及治疗脊髓损伤的药物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838216B1 (en) * 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5288477A (en) * 1991-09-27 1994-02-22 Becton, Dickinson And Company Method for prognosticating response to cancer therapy
FI941572L (fi) * 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US6482795B1 (en) * 1997-01-30 2002-11-19 Myriad Genetics, Inc. Tumor suppressor designated TS10q23.3
WO1999001559A1 (en) * 1997-07-03 1999-01-14 Asahi Kasei Kogyo Kabushiki Kaisha Novel mapk kinase
WO1999044062A1 (en) 1998-02-25 1999-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cellular arrays for rapid molecular profiling
US6218114B1 (en) 1998-03-27 2001-04-17 Academia Sinica Methods for detecting differentially expressed genes
US6004755A (en) 1998-04-07 1999-12-21 Incyte Pharmaceuticals, Inc. Quantitative microarray hybridizaton assays
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
US6582946B1 (en) * 2001-03-12 2003-06-24 Applera Corporation Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US6727072B2 (en) * 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
US20030194734A1 (en) 2002-03-29 2003-10-16 Tim Jatkoe Selection of markers
SI1509230T1 (sl) * 2002-06-05 2007-06-30 Cedars Sinai Medical Center Gefitinib (iressa) za zdravljenje raka
US8067152B2 (en) * 2006-02-27 2011-11-29 The Fred Hutchinson Cancer Research Center Liver cancer biomarkers

Also Published As

Publication number Publication date
EP2413142A1 (de) 2012-02-01
US8129125B2 (en) 2012-03-06
US20120094311A1 (en) 2012-04-19
US8900820B2 (en) 2014-12-02
EP2114990B1 (de) 2011-11-02
EP2114990A4 (de) 2010-04-07
DK2114990T3 (da) 2012-01-16
EP2114990B9 (de) 2012-03-28
US20110189691A1 (en) 2011-08-04
DK2114990T5 (da) 2012-05-07
US20080206777A1 (en) 2008-08-28
WO2008106175A2 (en) 2008-09-04
EP2114990A2 (de) 2009-11-11
ES2412432T3 (es) 2013-07-11
EP2413142B1 (de) 2013-06-05
DK2413142T3 (da) 2013-07-22
US8088589B2 (en) 2012-01-03
ES2376978T3 (es) 2012-03-21
WO2008106175A3 (en) 2008-11-20
US20090263819A1 (en) 2009-10-22

Similar Documents

Publication Publication Date Title
DK2413142T3 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters reaktion på behandling med en EGFR-TK-inhibitor
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
CY1125190T1 (el) Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα
Carlberg et al. Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder
Marino et al. Prognostic significance of miR-34a in Ewing sarcoma is associated with cyclin D1 and ki-67 expression
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
BRPI0518086A (pt) métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
WO2006091776A3 (en) Biomarkers for predicting prostate cancer progression
BRPI0907637A8 (pt) biomarcadores p53
EA201291206A1 (ru) Мутация в mek1, придающая устойчивость к ингибиторам raf и mek
WO2008148115A8 (en) Methods, systems, and kits for evaluating multiple sclerosis
BR112014003877A2 (pt) biomarcadores de micro-rna e métodos de uso dos mesmos
JOP20190199B1 (ar) استخدام العوامل الحيوية في تحديد مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط prmt5
SI2838998T1 (en) EGFR AND ROS1 PRI CRAK
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
WO2010093450A3 (en) Pten phosphorylation-driven restistance to cancer treatment and altered prognosis
MX2014002144A (es) Metodo para predecir el beneficio clinico del tratamiento de los transtornos del desarrollo neurologico, neurologicos o neuropsiquiatricos.
Chernykh et al. Effect of expression of multidrug resistance genes in newly diagnosed multiple myeloma on the clinical course of the disease
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor